For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and development | 1,394 | 1,675 | 2,652* | 2,137 |
| General and administrative | 1,528 | 1,168 | 1,428* | 1,456 |
| Total operating expenses | 2,922 | 2,843 | 4,080 | 3,593 |
| Loss from operations | -2,922 | -2,843 | -4,080* | -3,593 |
| Interest expense | 5 | 2 | -6* | 6 |
| Other income, net | 59 | 61 | 97* | 112 |
| Total other income, net | 54 | 59 | 103* | 106 |
| Net loss | -2,868 | -2,784 | -3,977 | -3,487 |
| Basic EPS | -0.38 | -0.58 | -2.985 | -2.32 |
| Diluted EPS | -0.38 | -0.58 | -2.985 | -2.32 |
| Basic Average Shares | 7,473,898 | 4,797,196 | 1,332,533 | 1,500,409 |
| Diluted Average Shares | 7,473,898 | 4,797,196 | 1,332,533 | 1,500,409 |
PALISADE BIO, INC. (PALI)
PALISADE BIO, INC. (PALI)